Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter March 2016


A shift in thinking about the CV benefits of ARBs will lead to more use of ARBs instead of ACE inhibitors
   We're used to using ACEIs...since they have more CV outcomes data and SEEMED to have a bigger impact on CV events than ARBs. 
   And low-cost generic ACEIs have been available for years. 
   But patients in older ACEI studies were at higher CV risk due to more smoking, less use of statins, etc...than patients in newer ARB studies. So CV benefit appeared greater with ACEIs compared to ARBs. 

If you would like to access this month's full free article on Cardiology from Prescriber's letter, please click here

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129  and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE